Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Statin use and exacerbations in individuals with chronic obstructive pulmonary disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD)

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Midlife cardiorespiratory fitness and the long-term risk of chronic obstructive pulmonary disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Interstitial lung abnormalities in people with HIV infection and uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic variation at PPP1R3B increases hepatic CT attenuation and interacts with prandial status on plasma glucose

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Repositioning of the global epicentre of non-optimal cholesterol

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: We tested the hypothesis that statin use in individuals with COPD is associated with a reduced risk of exacerbations.

METHODS: We identified 5794 individuals with COPD and a measurement of C reactive protein (CRP) in the Copenhagen General Population Study (2003-2008). During 3 years of follow-up we recorded exacerbations with hospital admissions or oral corticosteroid treatment. In a nested case-control design, matching on age, gender, smoking, COPD severity and comorbidity, we estimated the association between statin use and exacerbations. In addition, we examined the association between statin use and high CRP (>3 mg/L), and the association between high CRP and exacerbations during follow-up.

RESULTS: Statin use was associated with reduced odds of exacerbations in crude analysis, OR=0.68 (95% CI 0.51 to 0.91, p=0.01), as well as in multivariable conditional logistic regression analysis, OR=0.67 (0.48 to 0.92, p=0.01). However, in the subgroup with the most severe COPD and without cardiovascular comorbidity, we observed a null association between statin use and exacerbations, OR=1.1 (0.5 to 2.1, p=0.83). Furthermore, statin use was associated with reduced odds of a high CRP, OR=0.69 (0.56 to 0.85, p<0.001), and a high CRP was associated with an increased risk of exacerbations, HR=1.62 (1.35 to 1.94, p<0.001). We estimated the percentage of excess risk of the association of statin use with exacerbations possibly mediated through a reduction of CRP to be 14% (4-51%).

CONCLUSIONS: Statin use was associated with reduced odds of exacerbations in individuals with COPD from the general population, although this was not apparent in those with the most severe COPD without cardiovascular comorbidity. Statins may thus only associate with reduced risk of exacerbations in patients with COPD with coexisting cardiovascular disease.

Original languageEnglish
JournalThorax
Volume70
Pages (from-to)33-40
ISSN0040-6376
DOIs
Publication statusPublished - 2015

Bibliographical note

Thorax 2015;70:33-40

ID: 44744350